ACOG.US Alpha Cognition Inc

Healthcare Biotechnology USA Stocks
8.56 USD
Close of Nov 13, 2026
4.50 10.14
Market cap
USD 186M
P/E
-
P/B
3.54x
ROE
-57.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ACOG.US undervalued?

Graham number

The Graham number of Alpha Cognition Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alpha Cognition Inc fundamental analysis

No fundamental analysis for Alpha Cognition Inc yet.

Alpha Cognition Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alpha Cognition Inc

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation…

Full company profile